Tradition Capital Management LLC raised its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 89.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,856 shares of the biopharmaceutical company’s stock after buying an additional 42,495 shares during the period. Bristol-Myers Squibb comprises 1.9% of Tradition Capital Management LLC’s investment portfolio, making the stock its 14th largest position. Tradition Capital Management LLC owned 5,490.07% of Bristol-Myers Squibb worth $5,727,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. Sunbelt Securities Inc. increased its stake in Bristol-Myers Squibb by 20.1% during the third quarter. Sunbelt Securities Inc. now owns 5,507 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 920 shares during the last quarter. Advisor Partners LLC boosted its holdings in shares of Bristol-Myers Squibb by 6.9% during the third quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock valued at $2,356,000 after acquiring an additional 2,382 shares during the period. Obermeyer Wood Investment Counsel Lllp boosted its holdings in shares of Bristol-Myers Squibb by 32.0% during the third quarter. Obermeyer Wood Investment Counsel Lllp now owns 19,819 shares of the biopharmaceutical company’s stock valued at $1,263,000 after acquiring an additional 4,805 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in shares of Bristol-Myers Squibb by 5.1% during the third quarter. Oregon Public Employees Retirement Fund now owns 396,387 shares of the biopharmaceutical company’s stock valued at $25,266,000 after acquiring an additional 19,068 shares during the period. Finally, Jacobi Capital Management LLC boosted its holdings in shares of Bristol-Myers Squibb by 97.1% during the third quarter. Jacobi Capital Management LLC now owns 13,406 shares of the biopharmaceutical company’s stock valued at $860,000 after acquiring an additional 6,606 shares during the period. 69.74% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently weighed in on the stock. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Wednesday, October 25th. Jefferies Group reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price objective for the company in a report on Wednesday, September 27th. UBS Group reissued a “buy” rating and issued a $72.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Finally, SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $65.11.
Shares of Bristol-Myers Squibb Co (BMY) opened at $59.92 on Wednesday. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $98,070.00, a P/E ratio of 23.59, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the prior year, the company posted $0.77 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. equities analysts forecast that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.67%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 62.99%.
WARNING: This report was first posted by BBNS and is owned by of BBNS. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://baseballnewssource.com/markets/tradition-capital-management-llc-raises-position-in-bristol-myers-squibb-co-bmy/1822202.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.